d3-pcbanner-33.jpg d3-phbanner.jpg
Clinical Trials
A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD5044 in Healthy Subjects

“A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD5044 in Healthy Subjects”, this study is ongoing in Australia. The study has completed enrolment in the single dose-escalation phase, and is currently in the multiple dose-escalation enrolment phase.

RBD5044 is a GalNAc-siRNA drug being developed for treatment of triglycerides (TGs)-type hypertriglyceridemia. RBD5044 inhibits the expression of APOC3 (Apolipoprotein C-III) to reduce the TGs level in blood by increasing the uptake of lipoprotein lipase and hepatocyte receptor-mediated residual particle and elevating the hydrolysis of triglycerides (TGs) on triglyceride-rich lipoproteins (TRLs).

联系

如果您想了解更多关于本研究或研究药物的信息,欢迎联系项目负责人,她(他)将更为详细的为您介绍本项目,并安排您进行相应的检查。

石莹
ying.shi@smo-clinplus.com
冒建培
ianpei.mao@smo-clinplus.com
胡金慧
jinhui.hu@smo-clinplus.com